| Literature DB >> 33290061 |
Samantha Caputo1,2, Simona Di Martino1,2, Vincenzo Cilibrasi1,2, Piero Tardia1,2, Marco Mazzonna1,2, Debora Russo1,3, Ilaria Penna1,3, Maria Summa1,4, Sine Mandrup Bertozzi1,4, Natalia Realini1,2, Natasha Margaroli1,2, Marco Migliore1,2, Giuliana Ottonello1,4, Min Liu5, Peter Lansbury5, Andrea Armirotti1,4, Rosalia Bertorelli1,4, Soumya S Ray5, Renato Skerlj5, Rita Scarpelli1,2.
Abstract
Acid ceramidase (AC) is a cysteine hydrolase that plays a crucial role in the metabolism of lysosomal ceramides, important members of the sphingolipid family, a diversified class of bioactive molecules that mediate many biological processes ranging from cell structural integrity, signaling, and cell proliferation to cell death. In the effort to expand the structural diversity of the existing collection of AC inhibitors, a novel class of substituted oxazol-2-one-3-carboxamides were designed and synthesized. Herein, we present the chemical optimization of our initial hits, 2-oxo-4-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 8a and 2-oxo-5-phenyl-N-(4-phenylbutyl)oxazole-3-carboxamide 12a, which resulted in the identification of 5-[4-fluoro-2-(1-methyl-4-piperidyl)phenyl]-2-oxo-N-pentyl-oxazole-3-carboxamide 32b as a potent AC inhibitor with optimal physicochemical and metabolic properties, showing target engagement in human neuroblastoma SH-SY5Y cells and a desirable pharmacokinetic profile in mice, following intravenous and oral administration. 32b enriches the arsenal of promising lead compounds that may therefore act as useful pharmacological tools for investigating the potential therapeutic effects of AC inhibition in relevant sphingolipid-mediated disorders.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33290061 PMCID: PMC7770833 DOI: 10.1021/acs.jmedchem.0c01561
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446